Tobacco-Attributable Age-Related Macular Degeneration Vision Impairment in Japan: A National and Prefecture-Level Analysis From 1990 to 2040
Luoming Huang, Li Cong, Andrzej Grzybowski

TL;DR
This study examines how smoking affects vision loss from AMD in Japan, showing that tobacco control and healthcare policies have reduced the burden despite population aging.
Contribution
The study provides a national and prefecture-level analysis of AMD vision impairment trends and tobacco's role in Japan from 1990 to 2040.
Findings
AMD-related vision impairment cases increased by 159% from 1990 to 2021, but age-standardized rates declined.
Tobacco's contribution to AMD-related DALYs decreased by 36.3% due to effective tobacco control policies.
Projections suggest a 42.51% increase in AMD cases by 2040, with differing trends between males and females.
Abstract
This study aimed to analyze the spatiotemporal burden of vision impairment due to age-related macular degeneration (AMD) in Japan from 1990 to 2021, projecting to 2040. Using data from the Global Burden of Disease (GBD) study, we systematically analyzed the prevalence, disability-adjusted life years (DALYs), and temporal trends of vision impairment due to AMD in Japan from 1990 to 2021 and projected disease burden to 2040. We also quantified the burden of vision impairment due to AMD attributable to tobacco. From 1990 to 2021, the number of AMD-related vision impairment cases increased by 159% to 93,310 (95% uncertainty interval [UI], 78,103–112,033); DALYs increased by 134% to 8907 (95% UI, 5984–12,298). However, the age-standardized prevalence rates declined from 22.3 to 19.73 per 100,000, and DALY rates decreased from 2.34 to 1.94. Prevalence was slightly higher in females,…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRetinal Diseases and Treatments · Ophthalmology and Visual Impairment Studies · Antioxidant Activity and Oxidative Stress
